Literature DB >> 374089

Disposition of guanethidine during chronic oral therapy.

J H Hengstmann, F C Falkner.   

Abstract

The plasma level and urinary excretion rate of guanethidine have been measured in 30 patients during oral maintenance therapy, and in 5 patients following discontinuous of therapy. A significant correlation was found between the daily average urinary excretion and the maintenance dose, although wide interindividual variation was noted among patients maintained on the same dose. A statistically significant correlation was also observed between the area under the plasma level curve during the dose interval and the oral maintenance dose. After discontinuation of chronic therapy, the half-life of 1.5 days of the initial phase of elimination was essentially in agreement with the half-life of almost 2 days determined in acute studies. In addition, a second phase of elimination with a half-life of 4 to 8 days was observed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 374089     DOI: 10.1007/bf00609875

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  RESERPINE-INDUCED RELEASE OF DRUGS FROM SYMPATHETIC NERVE ENDINGS.

Authors:  C C CHANG; E COSTA; B B BRODIE
Journal:  Life Sci (1962)       Date:  1964-08

2.  Guanethidine; hypotensive drug with prolonged action.

Authors:  A W LEISHMAN; H L MATTHEWS; A J SMITH
Journal:  Lancet       Date:  1959-12-12       Impact factor: 79.321

3.  The physiological disposition of etilefrine in man.

Authors:  J H Hengstmann; U Weyand; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

4.  Quantitative determination of guanethidine and other guanido-containing drugs in biological fluids by gas chromatography with flame ionization detection and multiple ion detection.

Authors:  J H Hengstmann; F C Falkner; J T Watson; J Oates
Journal:  Anal Chem       Date:  1974-01       Impact factor: 6.986

5.  The influence of renal function on plasma levels, urinary excretion, metabolism, and antihypertensive effect of guanethidine (ismelin) in man.

Authors:  K H Rahn
Journal:  Clin Nephrol       Date:  1973 Jan-Feb       Impact factor: 0.975

6.  Comparison of antihypertensive efficacy, intestinal absorption, and excretion of guanethidine in hypertensive patients.

Authors:  K H Rahn; L I Goldberg
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

7.  The fate of guanethidine in two hypertensive patients.

Authors:  C McMartin; R K Rondel; J Vinter; B R Alln; P M Humberstone; A W Leishman; G Sandler; J L Thirkettle
Journal:  Clin Pharmacol Ther       Date:  1970 May-Jun       Impact factor: 6.875

8.  The absorption and metabolism of guanethidine in hypertensive patients requiring different doses of the drug.

Authors:  C McMartin; P Simpson
Journal:  Clin Pharmacol Ther       Date:  1971 Jan-Feb       Impact factor: 6.875

9.  [Plasma level and urinary excretion of guanethidine in hypertensive patients].

Authors:  K H Rahn
Journal:  Arzneimittelforschung       Date:  1971-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.